All Articles

Ophthalmic Product Development Insights
How to approach the occasional situation in which this chronic condition suddenly becomes acute.
Deviations should be rare. The protocol helps to keep the study on track.
Customer Success Stories: Celebrating Your Big Wins in 2014-2015
SkQ1 is the first mitochondria-targeted antioxidant to reach clinical phase of development for an ophthalmic indication
U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc.
Communication and proper preparation are necessary for a successful study.
The exciting world of stem cell therapy is the cutting edge of medical research. Here’s how it intersects with ophthalmology.
Researchers are exploring disease-modifying treatment options and not just symptomatic relief.